PO Box 58871
London SE15 9BE, UK
info@cedillapublishing.com
+44 (0)7794 485294


Cedilla Publishing highly commended at 2016 BMA Medical Book Awards
We are delighted to announce that our GP pain handbook, The 10-minute consultation: persistent pain, was highly commended in the primary health care category at the 2016 BMA Medical Book Awards.

The GP judging panel commented:
"Pain management is an increasingly challenging field in general practice and this [guide] brings together a lot of useful information. It is comprehensive while concise and includes a good range from the best scientific evidence through to holistic approaches. I checked some of the sections and found them to be both accurate and up-to-date. It is a good introduction to the subject."

If you are interested in purchasing copies or translation rights, please contact Sarah Findlay on +44 (0)7794 485294 or email info@cedillapublishing.com.

News Archive

Babies in prams 'exposed to more pollution'
Tue, 14 Aug 2018 15:02:53 GMT
Infants in prams can be exposed to up to 60% more pollution than adults, a study suggests.
The radio 'saved my little girl's life'
Tue, 14 Aug 2018 07:50:45 GMT
A large trial in Burkina Faso suggests listening to the radio could improve child health.
Vaping 'can damage vital immune system cells'
Tue, 14 Aug 2018 02:47:31 GMT
E-cigarette vapour disables important immune cells in the lung and boosts inflammation.
Four new medicines cleared for use on NHS Scotland
Tue, 14 Aug 2018 10:58:38 +0100
The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema.
Xolair deemed ?breakthrough? therapy for food allergies
Tue, 14 Aug 2018 10:53:13 +0100
Roche/Novartis’ Xolair has been awarded breakthrough status in the US for treatment of severe allergic reactions after accidental exposure to foods allergens.
Draft guidelines reject NHS funding for Biogen?s Spinraza
Tue, 14 Aug 2018 10:46:29 +0100
The National Institute for Health and Care Excellence is not recommending NHS use of Biogen’s Spinraza for the rare genetic disorder spinal muscular atrophy (SMA) at this time.